Agilon Health price target lowered to $8 from $11 at JMP Securities

JMP Securities lowered the firm’s price target on Agilon Health to $8 from $11 and keeps an Outperform rating on the shares. While Q4 revenue exceeded consensus estimates, Agilon’s Q4 adjusted EBITDA trailed consensus, the analyst tells investors in a research note. The firm says that a guide down was likely expected and baked into shares, though the magnitude of the revision eclipsed expectations.